Studies have shown that tumors with BRCA2 mutations demonstrate enhanced sensitivity to DNA-damaging chemotherapy through failure to repair double-strand breaks, with overall response rates exceeding those of sporadic breast cancers treated with anthracycline-based regimens [43]. The gene discussed is BRCA2; the disease is breast carcinoma.